Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

TCR2 closes $125mm Series B round

27 Mar 2018

Executive Summary

TCR2 Therapeutics Inc. (immuno-oncology) raised $125mm through its Series B round. Curative Ventures and 6 Dimensions Capital co-led and were joined by additional new investors Redmile Group, ArrowMark Partners, Hillhouse Capital Group, Mirae Asset Financial Group, Syno Capital, Haitong International Securities, Lucion Group, Sirona Capital, Alexandria Venture Investments, and affiliates of Leerink Partners. Existing investors MPM Capital, F2 Ventures, and Cathay Fortune Capital Investment also participated.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By